CEO
Depixus, France
Gordon Hamilton is a founder and the CEO of Depixus, a Paris-based biotechnology company pioneering a powerful new technology for studying biomolecular interactions. He has led the company from its inception through to the present day. He previously worked as a Medical Director for ChemoCentryx, a US biopharmaceutical company developing drug targeting the chemokine system (recently acquired by Amgen), where he helped to advance several drugs through Phases I & II of clinical development. Prior to that he worked as a physician in the UK. He holds medical degrees from Oxford University and Imperial College and an MBA from INSEAD.